Zhou, Wen-jing <br/><br/>
Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein.  [electronic resource] 

 -  British journal of pharmacology  Jul 2012 
 - 1669-83 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1476-5381 
<br/><br/><label>Standard No.: </label>10.1111/j.1476-5381.2012.01849.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>ATP Binding Cassette Transporter, Subfamily B, Member 1--antagonists & inhibitors<br/>Adenosine Triphosphatases--metabolism<br/>Animals<br/>Antineoplastic Agents--pharmacology<br/>Cell Line, Tumor<br/>Crizotinib<br/>Doxorubicin--pharmacokinetics<br/>Drug Resistance, Multiple--drug effects<br/>Drug Resistance, Neoplasm--drug effects<br/>Female<br/>Humans<br/>Mice<br/>Mice, Nude<br/>Neoplasms--drug therapy<br/>Paclitaxel--therapeutic use<br/>Protein Kinase Inhibitors--pharmacology<br/>Pyrazoles--pharmacology<br/>Pyridines--pharmacology<br/>Rhodamine 123--pharmacokinetics<br/>Tumor Burden--drug effects<br/>Xenograft Model Antitumor Assays